Synthesis of glycoconjugate vaccines in genetically engineered bacterial cells

Current Organic Chemistry

Volumn 18, Issue 8, 2014, Pages 960-963

  Fernandez, Fabiana ^a   Wacker, Michael ^a  

^a GlycoVaxyn AG   (Switzerland)

Author keywords

Bacterial vaccines; Bioconjugates; Chemical conjugation; Conjugate vaccines; Glycosylation; Production of glycoconjugates in e. coli

Indexed keywords

ANTIGENS; CARBOHYDRATES; ESCHERICHIA COLI; PROTEINS;

BACTERIAL CELLS; BACTERIAL VACCINE; BIOCONJUGATES; CHEMICAL CONJUGATION; COLI; CONJUGATE VACCINE; GLYCOCONJUGATES; GLYCOSYLATIONS; MANUFACTURING PROCESS; PRODUCTION OF GLYCOCONJUGATE IN E.;

VACCINES;

EID: 84904042793     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/138527281808140616154704     Document Type: Article

References (31)

1. Plotkin, S.A.; Orenstein, W.A.; Offit, P.A., Vaccines, 5th ed.; Saunders: Philadelphia, Pa.; [London], 2008; p xvii, 1725 p.
2. Henics, T.; Winkler, B.; Pfeifer, U.; Gill, S.R.; Buschle, M.; von Gabain, A.; Meinke, A.L. Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens. Biotechniques, 2003, 35(1), 196-202204, 206 passim.
3. Sette, A.; Rappuoli, R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity, 2010, 33(4), 530-541.
4. Zauner, W.; Lingnau, K.; Mattner, F.; von Gabain, A.; Buschle, M. Defined synthetic vaccines. Biol. Chem., 2001, 382(4), 581-595.
5. Avery, O.T.; Goebel, W.F. Chemo-immunological studies on conjugated carbohydrate-proteins. II Immunological specificity of synthetic sugarproteins. J. Exp. Med., 1929, 50, 521-533.
6. Anderson, P. Antibody responses to Haemophilus influenzae type B and diphtheria toxin induced by conjugates of oligosaccharides of the type B capsule with the nontoxic protein CRM197. Infect. Immun., 1983, 39(1), 233-238.
7. Schneerson, R.; Barrera, O.; Sutton, A.; Robbins, J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide- protein conjugates. J. Exp. Med., 1980, 152(2), 361-376.
8. Ada, G.; Isaacs, D. Carbohydrate-protein conjugate vaccines. Clin. Microbiol. Infect., 2003, 9(2), 79-85.
9. Lockhart, S. Conjugate vaccines. Expert Rev. Vaccines, 2003, 2(5), 633-648.
10. Frasch, C.E. Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges. Vaccine, 2009, 27(46), 6468-6470.
11. Chu, C.; Schneerson, R.; Robbins, J.B.; Rastogi, S.C. Further studies on the immunogenicity of Haemophilus influenzae type B and pneumococcal type 6A polysaccharide-protein conjugates. Infect. Immun., 1983, 40(1), 245-256.
12. Lees, A.; Nelson, B.L.; Mond, J.J. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in proteinpolysaccharide conjugate vaccines and immunological reagents. Vaccine, 1996, 14(3), 190-198.
13. Whitfield, C. Biosynthesis of lipopolysaccharide O antigens. Trends Microbiol., 1995, 3(5), 178-185.
14. Whitfield, C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu. Rev. Biochem., 2006, 75, 39-68.
15. Wacker, M.; Linton, D.; Hitchen, P.G.; Nita-Lazar, M.; Haslam, S.M.; North, S.J.; Panico, M.; Morris, H.R.; Dell, A.; Wren, B.W.; Aebi, M. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science, 2002, 298(5599), 1790-1793.
16. Alaimo, C.; Catrein, I.; Morf, L.; Marolda, C.; Callewaert, N.; Valvano, M.; Feldman, M.; Aebi, M. Two distinct but interchangeable mechanisms for flipping of lipid-linked oligosaccharides. Embo. J., 2006, 25(5), 967-976.
17. Linton, D.; Dorrell, N.; Hitchen, P.G.; Amber, S.; Karlyshev, A.V.; Morris, H.R.; Dell, A.; Valvano, M.A.; Aebi, M.; Wren, B.W. Functional analysis of the Campylobacter jejuni N-linked protein glycosylation pathway. Mol. Microbiol., 2005, 55(6), 1695-1703.
18. Kowarik, M.; Young, N.M.; Numao, S.; Schulz, B.L.; Hug, I.; Callewaert, N.; Mills, D.C.; Watson, D.C.; Hernandez, M.; Kelly, J.F.; Wacker, M.; Aebi, M. Definition of the bacterial N-glycosylation site consensus sequence. Embo. J., 2006, 25(9), 1957-1966.
19. Feldman, M.F.; Wacker, M.; Hernandez, M.; Hitchen, P.G.; Marolda, C.L.; Kowarik, M.; Morris, H.R.; Dell, A.; Valvano, M.A.; Aebi, M. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc. Natl. Acad. Sci. USA, 2005, 102(8), 3016-3021.
20. Cuccui, J.; Thomas, R.M.; Moule, M.G.; D'Elia, R.V.; Laws, T.R.; Mills, D.C.; Williamson, D.; Atkins, T.P.; Prior, J.L.; Wren, B.W. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis. Open Biol., 2013, 3(5), 130002.
21. Ihssen, J.; Kowarik, M.; Dilettoso, S.; Tanner, C.; Wacker, M.; Thony- Meyer, L. Production of glycoprotein vaccines in Escherichia coli. Microb. Cell. Fact., 2010, 9, 61.
22. Ihssen, J.; Kowarik, M.; Wiesli, L.; Reiss, R.; Wacker, M.; Thony-Meyer, L. Structural insights from random mutagenesis of Campylobacter jejuni oligosaccharyltransferase PglB. BMC Biotechnol., 2012, 12, 67.
23. Wacker, M.; Feldman, M.F.; Callewaert, N.; Kowarik, M.; Clarke, B.R.; Pohl, N.L.; Hernandez, M.; Vines, E.D.; Valvano, M.A.; Whitfield, C.; Aebi, M. Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. Proc. Natl. Acad. Sci. USA, 2006, 103(18), 7088-7093.
24. Wetter, M.; Kowarik, M.; Steffen, M.; Carranza, P.; Corradin, G.; Wacker, M. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component. Glycoconj. J., 2012, 30(5), 511-522.
25. Phalipon, A.; Tanguy, M.; Grandjean, C.; Guerreiro, C.; Belot, F.; Cohen, D.; Sansonetti, P.J.; Mulard, L.A. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J. Immunol., 2009, 182(4), 2241-2247.
26. Pozsgay, V.; Chu, C.; Pannell, L.; Wolfe, J.; Robbins, J.B.; Schneerson, R. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. USA, 1999, 96(9), 5194-5197.
27. Oberli, M.A.; Hecht, M.L.; Bindschadler, P.; Adibekian, A.; Adam, T.; Seeberger, P.H. A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem. Biol., 2011, 18(5), 580-588.
28. Schofield, L.; Hewitt, M.C.; Evans, K.; Siomos, M.A.; Seeberger, P.H. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature, 2002, 418(6899), 785-789.
29. Oberli, M.A.; Hecht, M.L.; Bindschadler, P.; Adibekian, A.; Adam, T.; Seeberger, P.H. A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem. Biol., 2011, 18(5), 580-588.
30. Schofield, L.; Hewitt, M.C.; Evans, K.; Siomos, M.A.; Seeberger, P.H. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature, 2002, 418(6899), 785-789.
31. Huang, Y.L.; Wu, C.Y. Carbohydrate-based vaccines: Challenges and opportunities. Expert Rev. Vaccines, 2010, 9(11), 1257-1274.